Light and shadows of the new therapies for haemophilia treatment in the COVID-19 era

Preview Coronavirus disease (covid-19) is an infectious disease caused by a novel coronavirus (SARS-CoV-2). The onset symptoms are similar to those of seasonal flu, but can easily develop into severe respiratory failure with the need for hospitalisation. In addition to these respiratory outcomes, some changes in coagulation parameters have been observed, especially in those patients more severely affected, who are therefore associated with a poor prognosis, as reported by Arachchillage and Laffan1. D-dimer, activated partial thromboplastin time (aPTT) and prothrombin time (PT) were increased in almost all patients, as reported by Tang et al.2 and Terpos et al.3 Disseminated intravascular coagulation (DIC) was considered as a predictor of mortality in patients with covid-192,4, while venous thromboembolism is considered an emerging issue due to patients’ characteristics: often elderly with severe comorbidities and long-term immobilisation. [ … ]